Kestra Medical stock price target reiterated at $32 by BTIG

BTIG reiterated a Buy and $32 price target on Kestra Medical (KMTS), implying ~66% upside from the $19.32 share price. The company reported fiscal Q3 EPS of -$0.61 (miss vs -$0.42 forecast) but revenue beat by ~7% and delivered 59% YoY revenue growth with a 48.75% gross margin; adjusted EBITDA loss was better than expected and the balance sheet shows more cash than debt. Piper Sandler maintained an Overweight rating, and BTIG expects revenue acceleration and margin expansion as the rental model scales.

Analysis

The wearable-defibrillator rental model creates a two-sided market opportunity: device economics improve as utilization rises, but scaling that fleet shifts risk into working capital, refurbishment logistics, and warranty/service operations. Expect near-term margin improvements to be driven more by fixed-cost absorption (service centers, telemetry platforms, repair networks) than by unit ASPs, which makes third-party logistics and remote-monitoring software vendors indirect beneficiaries.

Key catalysts cluster by horizon: days–weeks bring event-driven volatility around investor calls and the next quarterly release; months will reveal whether utilization and churn trends support sustained rental yields; 12–24 months are the make-or-break window for whether the model converts to positive free cash flow once refurbishment loops and inventory turns stabilize. Major tail risks that would reverse the thesis are regulation or reimbursement contractions, a product recall, or an incumbent pricing response that forces accelerated fleet depreciation.

Consensus appears to underweight balance-sheet and operational execution risk. Margin expansion narratives often ignore the timing mismatch between capital outlay to build rental inventory and the multi-month revenue stream per patient — that gap can make adjusted EBITDA look stronger than cash flow. If the company proves it can compress days-in-inventory and lower refurbishment cost per unit, the upside is underpriced; if not, equity downside could be sharp as investors reprice cash-conversion risk.

Key Decisions for Investors

• Initiate a tactical long position in KMTS sized 2–3% NAV with a 12–24 month horizon; scale on sequential confirmation of rental-utilization improvement (e.g., two consecutive quarters) and use a 30% trailing stop to limit execution risk—target 50–60% gross upside if operational metrics trend positively.
• Buy a defined-risk option spread to express the upside while limiting drawdown: purchase a 12–18 month call spread with long strike ~35% OTM and short strike ~80% OTM (size 1–2% NAV). Max loss = premium; payoff 3–6x if fleet economics re-rate the multiple.
• Pair trade to isolate execution: long KMTS / short a large incumbent defibrillator peer (1:1 dollar exposure) for 6–12 months to capture de-risked rental adoption upside while hedging sector/regulatory shocks; trim if relative performance fails to improve after the next quarter.
• Hedge downside around the next earnings call by buying a 3–6 month put spread (25% ITM / ATM) sized to offset 50% of the long position — protects against headline-driven drawdowns (regulatory, recall, or a clear utilization miss).